NCT07194005View on ClinicalTrials.gov

Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 4, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2028

Conditions
Gastric Cancer
Interventions
DRUG

Disitamab vedotin(RC48)

2.5 mg/kg, administered intravenously every 3 weeks (Q3W) on Day 1 of each cycle.

DRUG

Sintilimab

200 mg, administered intravenously, d1, every 3 weeks.

DRUG

S-1

Oral, 40-60 mg, twice daily (bid), d1-14, every 3 weeks.

DRUG

Oxaliplatin

130 mg/m², administered intravenously on Day 1 (d1), every 3 weeks.

Trial Locations (1)

200230

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER